Skip to main content

For information on the Change Healthcare cyber response:



For Providers - Get information on temporary funding assistance:

Find out about our temporary funding assistance program for those affected by payment services disruptions.

Drug Pipeline Insights Report

3 new first-in-class therapies coming

See how innovation is driving the latest product development.

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx­ | Published: April 2023

2023 will be a busy year for new pharmaceutical treatments.

Front cover and inside pages of the Optum Rx drug pipeline insights report

Welcome to the next issue of Drugs to Watch for 2023

In this Drug Pipeline Insights Report, we review:

  • Two respiratory syncytial virus (RSV) vaccines
  • A gene therapy for Duchenne muscular dystrophy (DMD)
  • First FDA-approved treatment for nonalcoholic steatohepatitis (NASH), a rare liver disease

Download now

Don't want to read the full report? Download the brief summary.

    View summary

    Related Content

    4 new drugs to watch this year

    Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.

    Which rules will impact pharmacy in 2023?

    2023 is already a busy year for pharmacy regulation. Read about the latest regulations that could impact you and your pharmacy benefit plan.

    3 new drugs to watch this fall

    As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.